ECSP088999A - Sintesis de un peptido insulinotropico - Google Patents
Sintesis de un peptido insulinotropicoInfo
- Publication number
- ECSP088999A ECSP088999A EC2008008999A ECSP088999A ECSP088999A EC SP088999 A ECSP088999 A EC SP088999A EC 2008008999 A EC2008008999 A EC 2008008999A EC SP088999 A ECSP088999 A EC SP088999A EC SP088999 A ECSP088999 A EC SP088999A
- Authority
- EC
- Ecuador
- Prior art keywords
- fragments
- synthesis
- solution
- solid phase
- fragment
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract 3
- 230000002473 insulinotropic effect Effects 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 6
- 239000012071 phase Substances 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 239000007790 solid phase Substances 0.000 abstract 2
- 239000006104 solid solution Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención está relacionada con la preparación de péptidos insulinotrópicos que se sintetizan utilizando una aproximación en fase sólida y en solución ("híbrida"). En general, la aproximación incluye la síntesis de tres fragmentos de péptido intermediarios diferentes utilizando la química de fase sólida. Entonces se utiliza la química de fase en solución para añadir material de aminoácidos adicional a uno de los fragmentos. Entonces se acoplan los fragmentos en la fase en solución sólida. La utlización de una pseudoprolina en uno de los fragmentos síntesis en fase sólida de ese fragmento y también facilita el subsiguiente acoplamiento en fase en solución de este fragmento con otros fragmentos. La presente invención es muy útil para la formación de péptidos insulinotrópicos como el GLP-1 7-36) y sus homólgos naturales y no naturales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81591906P | 2006-06-23 | 2006-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088999A true ECSP088999A (es) | 2009-01-30 |
Family
ID=38596729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008999A ECSP088999A (es) | 2006-06-23 | 2008-12-22 | Sintesis de un peptido insulinotropico |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US20080004429A1 (es) |
| EP (1) | EP2035451B1 (es) |
| JP (1) | JP4537495B2 (es) |
| KR (1) | KR101087859B1 (es) |
| CN (1) | CN101563364B (es) |
| AR (1) | AR061604A1 (es) |
| AT (1) | ATE466881T1 (es) |
| AU (1) | AU2007263043B2 (es) |
| BR (1) | BRPI0713575A2 (es) |
| CA (1) | CA2654610C (es) |
| CL (1) | CL2007001835A1 (es) |
| CR (1) | CR10463A (es) |
| CY (1) | CY1110186T1 (es) |
| DE (1) | DE602007006310D1 (es) |
| DK (1) | DK2035451T3 (es) |
| EC (1) | ECSP088999A (es) |
| ES (1) | ES2341588T3 (es) |
| HR (1) | HRP20100302T1 (es) |
| IL (1) | IL195421A0 (es) |
| MA (1) | MA30530B1 (es) |
| MX (1) | MX2008015935A (es) |
| MY (1) | MY144608A (es) |
| NO (1) | NO20084863L (es) |
| NZ (1) | NZ573093A (es) |
| PL (1) | PL2035451T3 (es) |
| PT (1) | PT2035451E (es) |
| RS (1) | RS51281B (es) |
| RU (1) | RU2448978C2 (es) |
| SI (1) | SI2035451T1 (es) |
| TW (1) | TWI331155B (es) |
| UA (1) | UA96602C2 (es) |
| WO (1) | WO2007147816A1 (es) |
| ZA (1) | ZA200810072B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5473925B2 (ja) * | 2007-10-27 | 2014-04-16 | コーデン ファーマ コロラド インコーポレイテッド | 固相および溶液相の組み合わせ技法を使用するインスリン分泌性ペプチドの合成 |
| WO2009074483A2 (en) * | 2007-12-11 | 2009-06-18 | F. Hoffmann-La Roche Ag | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| US20100317057A1 (en) * | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| US20100183876A1 (en) * | 2008-12-23 | 2010-07-22 | Hell Andre | Process for the Preparation of a Peptide Powder Form |
| EP2424888A2 (en) * | 2009-05-01 | 2012-03-07 | F. Hoffmann-La Roche AG | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| US20110313131A1 (en) | 2010-06-21 | 2011-12-22 | Christelle Carl | Reversed phase hplc purification of a glp-1 analogue |
| US20120157382A1 (en) | 2010-12-21 | 2012-06-21 | Siegfried Krimmer | Pharmaceutical glp-1 compositions having an improved release profile |
| EP2788110B1 (en) * | 2011-12-08 | 2018-10-17 | Pentair Water Pool and Spa, Inc. | Aquaculture system and method of operating a pump in such a system |
| ES2682253T3 (es) | 2011-12-29 | 2018-09-19 | Novo Nordisk A/S | Dipéptido que comprende un aminoácido no proteogénico |
| CN104936610A (zh) | 2012-11-13 | 2015-09-23 | 益普生制药股份有限公司 | Glp-1类似物的纯化方法 |
| WO2014077801A1 (en) | 2012-11-13 | 2014-05-22 | Ipsen Pharma S.A.S. | Purification process for preparing highly pure taspoglutide |
| GR20140100479A (el) * | 2014-09-23 | 2016-05-05 | Novetide, Ltd., | Συνθεση λιραγλουτιδης |
| CN119060201A (zh) * | 2018-03-09 | 2024-12-03 | 费森尤斯卡比有限公司 | 利拉鲁肽、索马鲁肽和glp-1的化学酶促合成 |
| EP3762408A1 (en) | 2018-03-09 | 2021-01-13 | Enzypep B.V. | Chemo-enzymatic synthesis of semaglutide, liraglutide and glp-1 |
| EP3864032B1 (en) * | 2018-10-09 | 2022-11-30 | Fresenius Kabi iPSUM S.r.l. | Process for the manufacture of glp-1 analogues |
| TWI799680B (zh) | 2019-01-29 | 2023-04-21 | 美商美國禮來大藥廠 | 製備gip/glp1雙重促效劑之方法 |
| TWI738260B (zh) * | 2019-03-25 | 2021-09-01 | 台灣神隆股份有限公司 | 純化利拉魯肽之方法 |
| US12269844B2 (en) | 2019-03-25 | 2025-04-08 | Scinopharm Taiwan, Ltd. | Process for purifying semaglutide and liraglutide |
| EP3753946A1 (en) | 2019-06-18 | 2020-12-23 | Fresenius Kabi iPSUM S.r.l. | Improved process for the preparation of high purity glucagon |
| US20220324936A1 (en) * | 2019-06-18 | 2022-10-13 | Fresenius Kabi Ipsum S.R.L. | Process for the manufacture of glucagon |
| US20230406900A1 (en) * | 2022-06-01 | 2023-12-21 | Scinopharm Taiwan, Ltd. | Process for preparing glucagon-like peptide-1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281335B1 (en) * | 1993-10-08 | 2001-08-28 | Coulter Corporation | Hybridoma and anti-KC-4 humanized monoclonal antibody |
| US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| JPH11503454A (ja) * | 1995-04-14 | 1999-03-26 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 成長ホルモン放出因子の類似体 |
| UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6281331B1 (en) * | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
| WO2000034331A2 (en) * | 1998-12-07 | 2000-06-15 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Analogues of glp-1 |
| US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
| US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| EP1701970A2 (en) * | 2003-12-31 | 2006-09-20 | F.Hoffmann-La Roche Ag | Methods for recovering cleaved peptide from a support |
-
2007
- 2007-06-19 DK DK07765481.2T patent/DK2035451T3/da active
- 2007-06-19 JP JP2009515856A patent/JP4537495B2/ja not_active Expired - Fee Related
- 2007-06-19 EP EP07765481A patent/EP2035451B1/en active Active
- 2007-06-19 RS RSP-2010/0267A patent/RS51281B/sr unknown
- 2007-06-19 MX MX2008015935A patent/MX2008015935A/es active IP Right Grant
- 2007-06-19 SI SI200730229T patent/SI2035451T1/sl unknown
- 2007-06-19 PT PT07765481T patent/PT2035451E/pt unknown
- 2007-06-19 AT AT07765481T patent/ATE466881T1/de active
- 2007-06-19 ES ES07765481T patent/ES2341588T3/es active Active
- 2007-06-19 NZ NZ573093A patent/NZ573093A/en not_active IP Right Cessation
- 2007-06-19 UA UAA200900414A patent/UA96602C2/ru unknown
- 2007-06-19 CN CN200780023265.1A patent/CN101563364B/zh not_active Expired - Fee Related
- 2007-06-19 CA CA2654610A patent/CA2654610C/en not_active Expired - Fee Related
- 2007-06-19 RU RU2009101969/04A patent/RU2448978C2/ru not_active IP Right Cessation
- 2007-06-19 BR BRPI0713575-0A patent/BRPI0713575A2/pt not_active IP Right Cessation
- 2007-06-19 AU AU2007263043A patent/AU2007263043B2/en not_active Ceased
- 2007-06-19 PL PL07765481T patent/PL2035451T3/pl unknown
- 2007-06-19 MY MYPI20085211A patent/MY144608A/en unknown
- 2007-06-19 WO PCT/EP2007/056052 patent/WO2007147816A1/en not_active Ceased
- 2007-06-19 KR KR1020087031096A patent/KR101087859B1/ko not_active Expired - Fee Related
- 2007-06-19 HR HR20100302T patent/HRP20100302T1/hr unknown
- 2007-06-19 DE DE602007006310T patent/DE602007006310D1/de active Active
- 2007-06-21 US US11/821,017 patent/US20080004429A1/en not_active Abandoned
- 2007-06-21 AR ARP070102735A patent/AR061604A1/es not_active Application Discontinuation
- 2007-06-22 CL CL200701835A patent/CL2007001835A1/es unknown
- 2007-06-22 TW TW096122579A patent/TWI331155B/zh not_active IP Right Cessation
-
2008
- 2008-11-19 NO NO20084863A patent/NO20084863L/no not_active Application Discontinuation
- 2008-11-20 IL IL195421A patent/IL195421A0/en unknown
- 2008-11-26 ZA ZA200810072A patent/ZA200810072B/xx unknown
- 2008-11-26 CR CR10463A patent/CR10463A/es not_active Application Discontinuation
- 2008-12-22 EC EC2008008999A patent/ECSP088999A/es unknown
- 2008-12-25 MA MA31510A patent/MA30530B1/fr unknown
-
2010
- 2010-06-11 CY CY20101100519T patent/CY1110186T1/el unknown
-
2011
- 2011-05-11 US US13/105,435 patent/US20110213082A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061604A1 (es) | Sintesis de un peptido insulinotropico | |
| AR069608A1 (es) | Metodo para obtener peptidos insulinotropicos utilizando una combinacion de tecnicas en fase solida y en solucion | |
| CY1125302T1 (el) | Συναγωνιστες γλυκαγονης και glp-1 για την αγωγη της παχυσαρκιας | |
| PE20170954A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| PA8830501A1 (es) | Co-agonistas del receptor de glucagon/glp-1 | |
| EP2344519A4 (en) | C-TERMINAL FRUCTIONS OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) | |
| ECSP15014133A (es) | Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida | |
| AR080229A1 (es) | Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23) | |
| DK1987052T3 (da) | Syntese af glucagonlignende peptider | |
| PE20090726A1 (es) | Anticuerpos anti-ige apoptoticos | |
| AR076977A1 (es) | Proteinas precursoras repetitivas autoensambladas | |
| AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
| CL2013003688A1 (es) | Peptido coagonista del receptor de glucagon/glp-1; conjugado de dicho peptido; composicion farmacéutica; uso del peptido para tratar una enfermedad seleccionada del grupo de síndrome metabólico, diabetes, obesidad, esteatosis hepática y una enfermedad neurodegenerativa. | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| PE20090763A1 (es) | Polipetidos, dominios variables de anticuerpos y antagonistas | |
| ECSP12012181A (es) | Nuevos péptidos y métodos para su preparación y uso | |
| CL2008000664A1 (es) | Proteina aislada que comprende un polipeptido del receptor iib de una variante de activina; acido nucleico aislado; vector recombinante que comprende dicho acido nucleico; celula huesped; composicion farmaceutica que comprende dicha proteina; uso de | |
| HN2009001593A (es) | Coagnistas de receptor de glucagon/glp-1 | |
| AR069409A1 (es) | Variantes de peptidos natriureticos de tipo c | |
| AR066885A1 (es) | Proteinas de fusion natriureticas | |
| EA201592281A1 (ru) | Новые модуляторы рецептора glp-1 | |
| GT201200236A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
| PA8738401A1 (es) | Proteinas de fusion de exendina | |
| CO6382161A2 (es) | Moleculas biespecificas de union a egfr/igfir | |
| AR087020A1 (es) | Polipeptidos de fusion de relaxina y usos de los mismos |